Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6937950 | 1.00 | PTGS1 (0.60) | PTGS1PTGS2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL8468243 | 0.98 | PTGS1 (0.58) | PTGS1PTGS2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL8465297 | 0.98 | PTGS1 (0.58) | PTGS1PTGS2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL8468016 | 0.98 | PTGS1 (0.58) | PTGS1PTGS2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL8888852 | 0.93 | PTGS1 (0.50) | PTGS1PTGS2SMN1; SMN2MEN1KMT2A | |
| Zinc Ion SCHEMBL8465869 | 0.92 | PTGS1 (0.51) | PTGS1PTGS2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL8465887 | 0.89 | ALDH1A1 (0.54) | PTGS1PTGS2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4400113 | 0.86 | ALDH1A1 (0.58) | PTGS1PTGS2MEN1KMT2AALDH1A1 | |
| SCHEMBL8887050 | 0.86 | MGLL (0.48) | PTGS1PTGS2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL8886884 | 0.86 | MGLL (0.48) | PTGS1PTGS2SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12408914-B2 | Systems and methods for customizing mechanical strength in stimuli-responsive bioabsorbable materials | CILAG GMBH INTERNATIONAL (CH) | 2025-09-09 | — | — | US | disclosed |
| EP-4543502-A1 | SYSTEMS AND METHODS FOR CUSTOMIZING MECHANICAL STRENGTH IN STIMULI-RESPONSIVE BIOABSORBABLE MATERIALS | Cilag GmbH International (CH) | 2025-04-30 | — | — | EP | disclosed |
| US-20250115626-A1 | BIFUNCTIONAL LINKER COMPRISING METAALLYLSILANE AND METHOD FOR PREPARING SAME | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2025-04-10 | — | — | US | disclosed |
| US-20240423617-A1 | SYSTEMS AND METHODS FOR CUSTOMIZING MECHANICAL STRENGTH IN STIMULI-RESPONSIVE BIOABSORBABLE MATERIALS | CILAG GMBH INTERNATIONAL (CH) | 2024-12-26 | — | — | US | disclosed |
| US-20240423620-A1 | COMPRESSIBLE SURGICAL ADJUNCTS, CARTRIDGES, AND CARTRIDGE ASSEMBLIES AND METHODS OF MAKING SURGICAL ADJUNCTS | CILAG GMBH INTERNATIONAL (CH) | 2024-12-26 | — | — | US | disclosed |
| WO-2024261659-A1 | SYSTEMS AND METHODS FOR CUSTOMIZING MECHANICAL STRENGTH IN STIMULI-RESPONSIVE BIOABSORBABLE MATERIALS | CILAG GMBH INTERNATIONAL (CH) | 2024-12-26 | — | — | WO | disclosed |
| US-20240382613-A1 | METHODS AND SYSTEMS FOR ULTRASOUND STIMULATED STRUCTURES AND DELIVERY OF THERAPEUTIC SPECIES | THE PENN STATE RESEARCH FOUNDATION | 2024-11-21 | — | — | US | disclosed |
| EP-4447944-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF THERAPEUTIC AND/OR DIAGNOSTIC SPECIES | THE PENN STATE RESEARCH FOUNDATION (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20240335540-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF THERAPEUTIC AND/OR DIAGNOSTIC SPECIES | PENN STATE RES FOUND (US) | 2024-10-10 | — | — | US | disclosed |
| CN-118613287-A | Compositions and methods for targeted delivery of therapeutic and/or diagnostic substances | 宾夕法尼亚州立大学研究基金会 | 2024-09-06 | — | — | CN | disclosed |
| US-6169186-B1 | LIQUID CRYSTALS AND LIQUID CRYSTALLINE POLYMERS | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-1016659-A1 | Bismaleimides comprising mesogenic groups and oligomeric liquid crystalline bismaleimides | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2000-07-05 | — | — | EP | disclosed |
| EP-0495544-B1 | Process for the synthesis of citraconimides | AKZO NOBEL NV (NL) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997003962-A1 | IMIDO PERESTERS AS INITIATORS OF POLYMERIZATION PROCESSES | AKZO NOBEL N.V. (NL) | 1997-02-06 | — | — | WO | disclosed |
| US-5523360-A | IMPROVES MELT-FLOW PROPERTIES | AKZO NOBEL N. V. (NL) | 1996-06-04 | — | — | US | disclosed |
| EP-0648240-A1 | PROCESS FOR THE MODIFICATION OF POLYPHENYLENE ETHER RESIN COMPOSITIONS | Akzo Nobel N.V. (NL) | 1995-04-19 | — | — | EP | disclosed |
| EP-0495545-B1 | Citraconimide (co)polymers and curing with anionic catalyst | AKZO NOBEL NV (NL) | 1994-12-28 | — | — | EP | disclosed |
| WO-1994001485-A1 | PROCESS FOR THE MODIFICATION OF POLYPHENYLENE ETHER RESIN COMPOSITIONS | AKZO NOBEL N.V. (NL) | 1994-01-20 | — | — | WO | disclosed |
| US-5221717-A | CITRACONIMIDE (CO)POLYMERS AND CURING WITH ANIONIC CATALYST | AKZO N.V. (NL) | 1993-06-22 | — | — | US | disclosed |
| EP-0495545-A1 | Citraconimide (co)polymers and curing with anionic catalyst | Akzo Nobel N.V. (NL) | 1992-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382613-A1 | METHODS AND SYSTEMS FOR ULTRASOUND STIMULATED STRUCTURES AND DELIVERY OF THERAPEUTIC SPECIES | PAICS, APEX1, ADM2 | PTGS1 954/4885PTGS2 837/4885SMN1; SMN2 585/4885 |
| US-20240335540-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF THERAPEUTIC AND/OR DIAGNOSTIC SPECIES | PAICS, CD47, CA13 | PTGS1 2128/4885PTGS2 1937/4885SMN1; SMN2 268/4885 |
| US-20250115626-A1 | BIFUNCTIONAL LINKER COMPRISING METAALLYLSILANE AND METHOD FOR PREPARING SAME | MSN, MTCL3, TLN1 | PTGS1 4202/4885PTGS2 4369/4885SMN1; SMN2 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.